Ensysce Biosciences Total Assets Growth & History (ENSC)
Ensysce Biosciences's total assets was $7.5M for fiscal 2025.
View full Ensysce Biosciences company overviewEnsysce Biosciences annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.5M | $1.9M | +33.15% |
| 2024 | 2024-12-31 | $5.6M | $2.9M | +106.69% |
| 2023 | 2023-12-31 | $2.7M | −$3.2M | −53.98% |
| 2022 | 2022-12-31 | $5.9M | −$10.5M | −64.15% |
| 2021 | 2021-12-31 | $16.4M | $16.1M | +4566.58% |
| 2020 | 2020-12-31 | $351,807 | −$196.2M | −99.82% |
| 2019 | 2019-12-31 | $196.5M | −$8.3M | −4.06% |
| 2018 | 2018-12-31 | $204.8M | $2.4M | +1.19% |
| 2017 | 2017-12-31 | $202.4M | — | — |
Ensysce Biosciences quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | −$2.6M | −46.95% |
| Q1 2026 | 2026-03-31 | $2.2M | −$2.4M | −53.00% |
| Q4 2025 | 2025-12-31 | $7.5M | $1.9M | +33.15% |
| Q3 2025 | 2025-09-30 | $3.2M | −$6.2M | −66.12% |
| Q2 2025 | 2025-06-30 | $5.6M | $2.8M | +99.40% |
| Q1 2025 | 2025-03-31 | $4.6M | −$462,316 | −9.11% |
| Q4 2024 | 2024-12-31 | $5.6M | $2.9M | +106.69% |
| Q3 2024 | 2024-09-30 | $9.4M | $6.2M | +191.57% |
| Q2 2024 | 2024-06-30 | $2.8M | −$3.6M | −56.03% |
| Q1 2024 | 2024-03-31 | $5.1M | $1.2M | +29.61% |
| Q4 2023 | 2023-12-31 | $2.7M | −$3.2M | −53.98% |
| Q3 2023 | 2023-09-30 | $3.2M | −$5.1M | −61.17% |
| Q2 2023 | 2023-06-30 | $6.4M | −$1.6M | −20.02% |
| Q1 2023 | 2023-03-31 | $3.9M | −$8.5M | −68.36% |
| Q4 2022 | 2022-12-31 | $5.9M | −$10.5M | −64.15% |
| Q3 2022 | 2022-09-30 | $8.3M | −$1.4M | −14.69% |
| Q2 2022 | 2022-06-30 | $7.9M | −$1.2M | −13.56% |
| Q1 2022 | 2022-03-31 | $12.4M | −$608,898 | −4.69% |
| Q4 2021 | 2021-12-31 | $16.4M | $16.1M | +4566.58% |
| Q3 2021 | 2021-09-30 | $9.7M | −$3.6M | −26.88% |
| Q2 2021 | 2021-06-30 | $9.2M | −$4.2M | −31.43% |
| Q1 2021 | 2021-03-31 | $13.0M | −$48.6M | −78.93% |
| Q4 2020 | 2020-12-31 | $351,807 | −$196.2M | −99.82% |
| Q3 2020 | 2020-09-30 | $13.3M | −$193.9M | −93.59% |
| Q2 2020 | 2020-06-30 | $13.4M | −$192.9M | −93.50% |
| Q1 2020 | 2020-03-31 | $61.6M | −$144.0M | −70.03% |
| Q4 2019 | 2019-12-31 | $196.5M | −$8.3M | −4.06% |
| Q3 2019 | 2019-09-30 | $207.2M | $3.2M | +1.56% |
| Q2 2019 | 2019-06-30 | $206.4M | $3.1M | +1.54% |
| Q1 2019 | 2019-03-31 | $205.6M | $2.7M | +1.32% |
| Q4 2018 | 2018-12-31 | $204.8M | $2.4M | +1.19% |
| Q3 2018 | 2018-09-30 | $204.0M | $203.6M | +50907.01% |
| Q2 2018 | 2018-06-30 | $203.2M | — | — |
| Q1 2018 | 2018-03-31 | $202.9M | — | — |
| Q4 2017 | 2017-12-31 | $202.4M | — | — |
| Q3 2017 | 2017-09-30 | $400,000 | — | — |
Ensysce Biosciences total assets trends
Over the last five fiscal years, Ensysce Biosciences's total assets increased from $351,807 to $7.5M, a change of $7.1M. The latest reported quarter, Q2 2026, shows $3.0M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ensysce Biosciences source filings ↗